Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

FDA Approves ADCIRCA(TM) (Tadalafil) Tablets For The Treatment Of Pulmonary Arterial Hypertension
United Therapeutics Corporation (Nasdaq: UTHR) announced that the United States Food and Drug Administration (FDA) has approved ADCIRCA(TM) (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). ADCIRCA is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.
buy viagra
Statement From CCF Against CDC Nominee Thomas Frieden
Following today"s announcement that President Obama nominated Dr. Thomas Frieden to head the Center for Disease Control and Prevention, the Center for Consumer Freedom"s Senior Research Analyst, J. Justin Wilson, released the following statement:
News of the day
Scientists Counteract Nanoparticle Lung Damage In Mice
Scientists have identified for the first time a mechanism by which nanoparticles cause lung damage and have demonstrated that it can be combated by blocking the process involved, taking a step toward addressing the growing concerns over the safety of nanotechnology.
Public Health

Aspirin And Secondary Prevention In Peripheral Artery Disease - A Perspective For The Early 21st Century

Mary McGrae McDermott, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and a contributing editor of JAMA, and Michael H. Criqui, M.D., M.P.H., of the University of California, San Diego School of Medicine, write that more research is needed regarding the outcomes of aspirin use by patients with PAD. "The meta-analysis by Berger et al enriches current understanding of the association of aspirin with cardiovascular outcomes in patients with PAD. However, based on the limitations of data available, the findings should not alter recommendations for aspirin as an important therapeutic tool for secondary prevention in patients with PAD. To best inform evidence-based clinical practice guidelines, more high-quality clinical trials are needed. Achieving this will require greater res for research and a larger critical mass of clinical investigators dedicated to the study of PAD." JAMA. 2009;301[18]:1927-1928. Journal of the American Medical Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009